MOORESVILLE, N.C., March 15, 2011 /PRNewswire/ -- Approximately 50,000 potassium iodide tablets have been donated by Nukepills.com to Tokushukai Hospital in Tokyo, Japan for immediate distribution to those affected by Japan's nuclear reactor crisis. This effort was facilitated by Dr. Alisa Suzuki Han, Radiologist at Brigham and Women's Hospital, a teaching facility of Harvard Medical School, in Boston, MA. The radiation-blocking drug, currently en route to Japan, will be distributed by the Tokushukai Medical Aid Team. "We are very pleased that these tablets will be given to people directly affected by the nuclear crisis," stated Troy Jones, President of Nukepills.com. "The efforts of Dr. Han and the Tokushukai Medical Aid Team are a wonderful example of professionals coming together to ensure the health and livelihood of those most in need."
Stockpiling of potassium iodide is recommended by health officials worldwide to prevent thyroid cancer of those exposed to radioactive iodine in the event of a nuclear reactor accident or detonation of a nuclear bomb. FDA approved in 1982, potassium iodide is available without a prescription. More information about FDA approved potassium iodide can be found online at http://www.nukepills.com.
Nukepills.com, celebrating its 12th year in business, is an Internet-based supplier of radiation emergency preparedness products that protect against dirty bomb radiation, nuclear reactor accidents and nuclear weapon fallout, and are used for radiation therapy/decontamination in hospitals. The company was founded in 1999 as a means of supplying FDA approved Iosat(TM) Potassium Iodide directly to the general public and now has international sales programs throughout Canada, Europe, Asia and the Middle East. In early 2009, Nukepills.com sold 5.4 million doses of FDA approved ThyroShield(TM) Liquid Potassium Iodide to Kuwait's Ministry of Health and expects Government Emergency Preparedness grants and civilian orders to continue to drive sales of all of its products well into 2011.